Posted by Michael Wonder on 25 Jul 2022
Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis
25 July 2022 - First and only long-acting C5 complement inhibitor showed early effect and demonstrated clinical improvement in activities of daily living.
Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive.
